Lab21 gets first Chinese approval for syphilis assay
This article was originally published in Clinica
An assay used in syphilis screening developed by UK firm Lab21 has been approved in China. The assay detects Treponema pallidum haemagglutination (TPHA). The Chinese market for in vitro diagnostics is worth around $1.5bn and is expanding by 15% annually, according to Lab21. "Our TPHA assay is already the leading syphilis assay in a number of key blood screening markets and we are delighted to make it available in another key region," the Cambridge-based company said.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.